Itching clue: antibodies linked to immunotherapy side effect

NCT ID NCT05689463

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at 100 cancer patients who have had chronic itching for over a month while on immunotherapy drugs like pembrolizumab or nivolumab. Researchers want to see if certain antibodies (BP180 and BP230) in the blood are linked to the itching. The goal is to better understand this side effect, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could help doctors identify which patients are at risk of severe itching during immunotherapy, leading to better monitoring.

What could go wrong

This is an observational study with only 100 participants. It does not test a treatment, so it may not lead to direct changes in care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH CHRONIC PRURITUS FOR MORE THAN 1 MONTH WHO HAVE RECEIVED IMMUNOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UHRouen

    RECRUITING

    Rouen, France

    Contact